(COO) The Cooper Companies - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 11.990m USD | Total Return: -20.8% in 12m

Contact Lenses, Fertility Services, Medical Devices, Contraception
Total Rating 49
Safety 81
Buy Signal -0.16
Medical Instruments & Supplies
Industry Rotation: +1.5
Market Cap: 12.0B
Avg Turnover: 136M
Risk 3d forecast
Volatility26.9%
VaR 5th Pctl4.36%
VaR vs Median-1.62%
Reward TTM
Sharpe Ratio-0.67
Rel. Str. IBD8.3
Rel. Str. Peer Group23.9
Character TTM
Beta0.403
Beta Downside0.642
Hurst Exponent0.551
Drawdowns 3y
Max DD46.97%
CAGR/Max DD-0.26
CAGR/Mean DD-0.66
EPS (Earnings per Share) EPS (Earnings per Share) of COO over the last years for every Quarter: "2021-04": 3.38, "2021-07": 3.41, "2021-10": 3.28, "2022-01": 3.24, "2022-04": 3.24, "2022-07": 3.19, "2022-10": 2.75, "2023-01": 2.9, "2023-04": 3.08, "2023-07": 3.35, "2023-10": 3.47, "2024-01": 0.85, "2024-04": 0.85, "2024-07": 0.96, "2024-10": 1.04, "2025-01": 0.92, "2025-04": 0.96, "2025-07": 1.1, "2025-10": 1.15, "2026-01": 1.1,
EPS CAGR: -40.40%
EPS Trend: -89.1%
Last SUE: 3.79
Qual. Beats: 4
Revenue Revenue of COO over the last years for every Quarter: 2021-04: 719.5, 2021-07: 763.4, 2021-10: 759.1, 2022-01: 787.2, 2022-04: 829.8, 2022-07: 843.4, 2022-10: 848.1, 2023-01: 858.5, 2023-04: 877.4, 2023-07: 930.2, 2023-10: 927.1, 2024-01: 931.6, 2024-04: 942.6, 2024-07: 1002.8, 2024-10: 1018.4, 2025-01: 964.7, 2025-04: 1002.3, 2025-07: 1060.3, 2025-10: 1065.2, 2026-01: 1024.099999,
Rev. CAGR: 7.11%
Rev. Trend: 99.4%
Last SUE: 0.09
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: COO The Cooper Companies

The Cooper Companies, Inc. (COO) is a global medical device manufacturer operating through two primary business segments: CooperVision and CooperSurgical. CooperVision focuses on the contact lens market, producing specialized spherical, toric, and multifocal lenses to correct conditions such as astigmatism and presbyopia. CooperSurgical provides medical devices and services for women’s healthcare, including fertility solutions, genomic services, and the Paragard intrauterine device.

The company operates within the Health Care Supplies sub-industry, a sector characterized by high barriers to entry due to stringent regulatory requirements and specialized manufacturing processes. Cooper’s business model relies on a diversified distribution network that targets hospitals, fertility clinics, and independent eye care professionals. For a deeper look into the companys valuation metrics, consider reviewing the detailed data on ValueRay. Headquartered in San Ramon, California, the company has maintained a presence in the medical technology market since 1958.

Headlines to Watch Out For
  • Myopia management adoption rates drive long-term revenue growth in contact lens segment
  • Expansion of fertility services portfolio increases high-margin CooperSurgical revenue share
  • Global contact lens market share gains offset rising manufacturing and logistics costs
  • Fluctuations in healthcare spending impact demand for elective women’s health procedures
  • Regulatory approval timelines for new contact lens technologies influence investor valuation metrics
Piotroski VR‑10 (Strict) 7.5
Net Income: 401.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.81 > 1.0
NWC/Revenue: 12.96% < 20% (prev 25.13%; Δ -12.17% < -1%)
CFO/TA 0.07 > 3% & CFO 866.4m > Net Income 401.4m
Net Debt (2.38b) to EBITDA (962.0m): 2.47 < 3
Current Ratio: 1.34 > 1.5 & < 3
Outstanding Shares: last quarter (196.7m) vs 12m ago -2.24% < -2%
Gross Margin: 64.24% > 18% (prev 0.67%; Δ 6.36k% > 0.5%)
Asset Turnover: 33.69% > 50% (prev 32.14%; Δ 1.55% > 0%)
Interest Coverage Ratio: 4.39 > 6 (EBITDA TTM 962.0m / Interest Expense TTM 105.5m)
Altman Z'' 4.51
A: 0.04 (Total Current Assets 2.13b - Total Current Liabilities 1.60b) / Total Assets 12.42b
B: 0.63 (Retained Earnings 7.77b / Total Assets 12.42b)
C: 0.04 (EBIT TTM 462.8m / Avg Total Assets 12.32b)
D: 1.84 (Book Value of Equity 7.46b / Total Liabilities 4.06b)
Altman-Z'' = 4.51 = AA
Beneish M -2.95
DSRI: 1.07 (Receivables 807.1m/716.4m, Revenue 4.15b/3.93b)
GMI: 1.04 (GM 64.24% / 67.00%)
AQI: 0.96 (AQ_t 0.66 / AQ_t-1 0.68)
SGI: 1.06 (Revenue 4.15b / 3.93b)
TATA: -0.04 (NI 401.4m - CFO 866.4m) / TA 12.42b)
Beneish M = -2.95 (Cap -4..+1) = A
What is the price of COO shares? As of May 22, 2026, the stock is trading at USD 62.85 with a total of 2,211,670 shares traded.
Over the past week, the price has changed by +4.09%, over one month by -6.61%, over three months by -24.22% and over the past year by -20.81%.
Is COO a buy, sell or hold? The Cooper Companies has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy COO.
  • StrongBuy: 9
  • Buy: 2
  • Hold: 8
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the COO price?
Analysts Target Price 91.1 44.9%
The Cooper Companies (COO) - Fundamental Data Overview as of 21 May 2026
P/E Trailing = 30.5721
P/E Forward = 13.3333
P/S = 2.8879
P/B = 1.3997
P/EG = 1.5649
Revenue TTM = 4.15b USD
EBIT TTM = 462.8m USD
EBITDA TTM = 962.0m USD
Long Term Debt = 1.88b USD (from longTermDebt, last quarter)
Short Term Debt = 620.7m USD (from shortTermDebt, last quarter)
Debt = 2.50b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.30m
Net Debt = 2.38b USD (calculated: Debt 2.50b - CCE 124.9m)
Enterprise Value = 14.37b USD (11.99b + Debt 2.50b - CCE 124.9m)
Interest Coverage Ratio = 4.39 (Ebit TTM 462.8m / Interest Expense TTM 105.5m)
EV/FCF = 29.25x (Enterprise Value 14.37b / FCF TTM 491.2m)
FCF Yield = 3.42% (FCF TTM 491.2m / Enterprise Value 14.37b)
FCF Margin = 11.83% (FCF TTM 491.2m / Revenue TTM 4.15b)
Net Margin = 9.67% (Net Income TTM 401.4m / Revenue TTM 4.15b)
Gross Margin = 64.24% ((Revenue TTM 4.15b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = 67.88% (prev 56.42%)
Tobins Q-Ratio = 1.16 (Enterprise Value 14.37b / Total Assets 12.42b)
Interest Expense / Debt = 0.90% (Interest Expense 22.4m / Debt 2.50b)
Taxrate = 31.95% (61.4m / 192.2m)
NOPAT = 315.0m (EBIT 462.8m * (1 - 31.95%))
Current Ratio = 1.34 (Total Current Assets 2.13b / Total Current Liabilities 1.60b)
Debt / Equity = 0.30 (Debt 2.50b / totalStockholderEquity, last quarter 8.36b)
Debt / EBITDA = 2.47 (Net Debt 2.38b / EBITDA 962.0m)
Debt / FCF = 4.84 (Net Debt 2.38b / FCF TTM 491.2m)
Total Stockholder Equity = 8.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.26% (Net Income 401.4m / Total Assets 12.42b)
RoE = 4.83% (Net Income TTM 401.4m / Total Stockholder Equity 8.31b)
RoCE = 4.54% (EBIT 462.8m / Capital Employed (Equity 8.31b + L.T.Debt 1.88b))
RoIC = 2.78% (NOPAT 315.0m / Invested Capital 11.32b)
WACC = 6.23% (E(11.99b)/V(14.49b) * Re(7.40%) + D(2.50b)/V(14.49b) * Rd(0.90%) * (1-Tc(0.32)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 0.0 | Cagr: -0.65%
[DCF] Terminal Value 85.98% ; FCFF base≈448.6m ; Y1≈475.2m ; Y5≈565.8m
[DCF] Fair Price = 67.38 (EV 15.52b - Net Debt 2.38b = Equity 13.15b / Shares 195.1m; r=6.23% [WACC]; 5y FCF grow 6.53% → 3.0% )
EPS Correlation: -89.08 | EPS CAGR: -40.40% | SUE: 3.79 | # QB: 4
Revenue Correlation: 99.35 | Revenue CAGR: 7.11% | SUE: 0.09 | # QB: 0
EPS current Quarter (2026-07-31): EPS=1.19 | Chg30d=+0.06% | Revisions=+20% | Analysts=15
EPS current Year (2026-10-31): EPS=4.62 | Chg30d=-0.06% | Revisions=+0% | GrowthEPS=+12.1% | GrowthRev=+5.6%
EPS next Year (2027-10-31): EPS=5.02 | Chg30d=+0.05% | Revisions=+0% | GrowthEPS=+8.7% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: +20%